Biotech Startups

InvenireX advances molecular diagnostics in life sciences through innovation in biotechnology. The company develops solutions for scientific research and healthcare applications.

1 investor

Inventia Life Science develops 3D cell culture platforms and standardized cell models for drug discovery, cancer research, and toxicity screening. The platform enables reproducible, human-relevant assays for pharmaceutical and biotech research teams.

1 investor

InveriTek provides high-throughput chemical screening using freshwater planarians, detecting systemic toxicity, neurotoxicity, and ecotoxicity through behavioral phenotyping in whole organisms. The service targets pharmaceutical, chemical, and environmental testing markets requiring toxicology assessment.

1 investor

InvisiShield Technologies develops products designed to prevent respiratory infections from airborne viruses such as COVID-19, influenza, and RSV. The company focuses on protecting people from illnesses caused by respiratory viruses.

1 investor

Invitrall develops long-lasting, disease-representative human skin organoids from reprogrammed human cells, combining cell reprogramming, organoids, and machine learning to create human preclinical models. Its platform supports efficacy and repeated-dose toxicity testing for pharmaceutical and dermocosmetics companies developing skin drugs and cosmetics, as an alternative to animal testing.

1 investor

Invitris develops cell-free protein synthesis platforms that enable rapid design, expression, and scalable production of complex proteins for biopharmaceuticals, industrial biotechnology, and agriculture.

1 investor

A company developing in vitro testing methods to assess respiratory sensitization for regulatory compliance in chemical and pharmaceutical industries.

1 investor

Invive applies epigenetics to life insurance, using a saliva test to measure lifestyle factors such as smoking and alcohol consumption as an alternative to the blood-test standard. It targets insurers, reinsurers, and distributors in the insurance industry.

1 investor

InVivo Bionics develops implantable sensor systems for medical monitoring, initially focused on bladder health in urology. The company combines expertise in sensor electronics, software, and medical devices to create minimally invasive monitoring solutions with potential applications across multiple organ systems.

1 investor

Invizius develops therapeutics targeting the complement system to treat kidney disease and other disorders driven by uncontrolled immune activation. The company was founded based on research from the University of Edinburgh and operates from Glasgow Biocity.

1 investor

Invoke develops personalized cancer treatments using computational biology to predict neoantigens with greater accuracy by modeling individual tumor evolution and immune dynamics. The company serves cancer patients through neoantigen prediction models designed for treatment personalization.

1 investor

Iolyx is a pharmaceutical company focused on developing treatments for ocular conditions. The company assembles a team of experienced scientists, clinicians, and regulatory experts in drug development and ophthalmology.

1 investor

iota Biosciences develops bioelectronic diagnostic and therapeutic devices using ultrasound technology to improve patient care. The company partners with Astellas Pharma to bring innovative medical technologies to market.

1 investor

Iovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.

1 investor

Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs) for various therapeutic segments, serving healthcare markets across 120 countries. The company operates fully-automated manufacturing facilities approved by major regulatory authorities including UK-MHRA, EDQM-Europe, and WHO-Geneva.

1 investor

Implant Preservation Devices develops orthopedic implant devices for medical and surgical applications. The company focuses on launching and commercializing orthopedic implant solutions across European and emerging markets.

1 investor

iPeace develops automated manufacturing systems for iPS cell production using biotech and engineering techniques to reduce production costs and enable mass manufacturing of clinical-grade stem cells. The company serves the regenerative medicine and pharmaceutical research sectors with mass-produced, personalized cell lines.

1 investor

IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Its technology originated from research at Weill Cornell Medicine and the Hospital for Special Surgery, and it is advancing these preclinical programs toward clinical applications.

1 investor

iQ Sense develops biosensing tools that combine nanotechnology and artificial intelligence to detect signs of animal disease earlier, serving the veterinary and animal-health industry. The company runs programs in the UK, Australia, and USA and partners with universities, research bodies, and animal-health companies.

1 investor

IQIRVO is a prescription medicine for treating primary biliary cholangitis (PBC) in adults, used either in combination with ursodeoxycholic acid or as a standalone treatment for patients unable to tolerate standard therapy.

1 investor

iRen develops medical technology for dialysis patients, enabling them to continue daily activities while undergoing treatment. The company aims to reduce the burden of dialysis on quality of life for people with kidney disease.

1 investor

iRiva Medical is a development-stage medical device company building neuromodulation technology platforms to treat patients with chronic diseases. A NuXcel spinoff based in Minneapolis, it develops implantable neuromodulation therapies targeting large patient populations with unmet clinical needs.

1 investor

IROA Technologies develops scientific measurement infrastructure for metabolomics, combining stable isotope chemistry, reference standards, authentic metabolite libraries, software, and data analytics to improve the accuracy and reproducibility of biological measurements. It serves researchers, clinicians, and innovators in the life sciences and biological research field.

1 investor

Ironic Biotech develops an iron supplement designed for better absorption and gastrointestinal tolerance, aimed at women affected by iron deficiency. The company operates in the biotech and women's health space.

1 investor